Even in Denmark — Novo Nordisk's dwelling market — an application for Wegovy to obtain general public health insurance coverage coverage was rejected within the grounds that its cost was incommensurate with its therapeutic value.Meantime, source constraints could dampen initial distribution inside a marketplace forecast being well worth $200 bi